Table 1 Some clinical characteristics at baseline

Age, years

66 ± 13

67 ± 14

67 ± 13

Male/Female, n (%)

38 (64)/21 (36)

38 (72)/15(28)

76(68)/36(32)

Weight, kg

79 ± 16

84 ± 19

81 ± 17

Height, m

1.71 ± 0.09

1.72 ± 0.1

1.72 ± 0.09

BMI, kg/m²

27 ± 4.7

28.0 ± 5.2

27.4 ± 4.9

mGFR, mL/min/1.73m²

22 ± 7

23 ± 9

23 ± 8

P-creatinine, μmol/L

242 ± 90

251 ± 92

247 ± 91

P-urea, mmol/L

16 ± 5

15 ± 5

15 ± 5

P-PTH, pmol/L

11 (9–17)

10 (7–16)

11(8–17)

P-Albumin, g/L

37 ± 4

38 ± 3

37 ± 3

B-Hemoglobin, g/L

129 ± 14

128 ± 14

128 ± 14

P-Potassium, mmol/L

4.3 ± 0.6

4.1 ± 0.5

4.2 ± 0.5

P-Calcium, mmol/L

2.3 ± 0.1

2.3 ± 0.1

2.3 ± 0.1

P-Ca × P, mmol²/L²

2.6 ± 0.7

2.5 ± 0.5

2.6 ± 0.6

P-Phosphate, mmol/L

1.2 ± 0.2

1.1 ± 0.2

1.1 ± 0.2

Base excess, mmol /L

−1.2 (−2.3–0.1)

−1.4 (− 3.2–0.0)

−1.2 (− 2.8–0.1)

P-CRP, mg/L

2.9 (1.3–5.9)

3.5 (1.5–6.9)

3.1 (1.3–6.1)

 Antihypertensive medication

55(93)

50(94)

105(94)

 Calcium channel blocker

33((56)

32(60)

65(58)

 Beta blocker

36(61)

37(70)

73(65)

 RAAS-blocker

37(63)

34(64)

71(63)

 Central antiadrenergic medication

8(14)

5(9)

13(12)

 Active vitamin D

38(64)

32(60)

70(62)

 Phosphate binder

24(41)

18(34)

42(38)

 Calcimimetic

1(2)

1(2)

2(2)

 Statin

33(56)

28(53)

61(54)

 Malignancy

8(14)

8(15)

16(14)

 Ischemic heart disease

11(19)

11(20)

22(20)

 Peripheral vascular disease

10(17)

13(25)

23(21)

 Left ventricular dysfunction

8(14)

3(6)

11(10)

 Diabetes mellitus

13(22)

17(32)

30(27)

 Systemic collagen vascular disease

5(8)

5(9)

10(9)

 Others (e.g. hypertension)

43(73)

40(75)

83(74)